Loss of SMAD4 promotes lung metastasis of colorectal cancer by accumulation of CCR1+ tumor-associated neutrophils through CCL15-CCR1 axis

Clinical Cancer Research

Volumn 23, Issue 3, 2017, Pages 833-844

  Yamamoto, Takamasa ^a   Kawada, Kenji ^a   Itatani, Yoshiro ^a,b   Inamoto, Susumu ^a   Okamura, Ryosuke ^a   Iwamoto, Masayoshi ^a   Miyamoto, Ei ^a   Chen Yoshikawa, Toyofumi F ^a   Hirai, Hideyo ^a   Hasegawa, Suguru ^a   Date, Hiroshi ^a   Taketo, Makoto M ^a   Sakai, Yoshiharu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CXCL15 CHEMOKINE; SMAD4 PROTEIN; UNCLASSIFIED DRUG; BETA CHEMOKINE; CCL15 PROTEIN, HUMAN; CCR1 PROTEIN, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN; SMAD4 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; TUMOR ASSOCIATED NEUTROPHIL; ANIMAL; BIOSYNTHESIS; CELL MOTION; COLORECTAL TUMOR; DEFICIENCY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; NEUTROPHIL CHEMOTAXIS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPORTER GENE; SCID MOUSE; SECONDARY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MACROPHAGE INFLAMMATORY PROTEINS; MICE; MICE, NUDE; MICE, SCID; MYELOID CELLS; NEOPLASM PROTEINS; NEUTROPHIL INFILTRATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CCR1; SMAD4 PROTEIN;

EID: 85012927614     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0520     Document Type: Article

References (43)

1. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: A 30-year population-based study. Gut 2010;59:1383-8.
2. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study. Surgery 2007;141:67-75.
3. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 2015;20:207-39.
4. Chen F, Sakai H, Miyahara R, Bando T, Okubo K, Date H. Repeat resection of pulmonary metastasis is beneficial for patients with colorectal carcinoma. World J Surg 2010;34:2373-8.
5. Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: A retrospective analysis. Ann Surg 2013;257:1059-64.
6. Hirosawa T, Itabashi M, Ohnuki T, Yamaguchi N, Sugihara K, Kameoka S. Japanese Society for Cancer of the Colon and Rectum (JSCCR) study group for pulmonary metastases from colorectal cancer. Prognostic factors in patients undergoing complete resection of pulmonary metastases of colorectal cancer: a multi-institutional cumulative follow-up study. Surg Today 2013;43:494-9.
7. Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg 2015;99:435-40.
8. Hirosawa T, Itabashi M, Ohnuki T, Yamaguchi N, Sugihara K, Kameoka S. Japanese Society for Cancer of the Colon and Rectum (JSCCR) study group for pulmonary metastases from colorectal cancer. Proposal of a new prognostic staging system for pulmonary metastases from colorectal cancer. Surg Today 2015;45:576-84.
9. Chen F, Hanaoka N, Sato K, Fujinaga T, Sonobe M, Shoji T, et al. Prognostic factors of pulmonary metastasectomy for colorectal carcinomas. World J Surg 2009;33:505-11.
10. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7.
11. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008;13:23-35.
12. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31.
13. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
14. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
15. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002;51:56-9.
16. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
17. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005;11:2606-11.
18. Voorneveld PW, Jacobs RJ, Kodach LL, Hardwick JC. A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Transl Oncol 2015;8:18-24.
19. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645-56.
20. Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 2007;39:467-75.
21. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 2010;107:13063-8.
22. Hirai H, Fujishita T, Kurimoto K, Miyachi H, Kitano S, Inamoto S, et al. CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis. Clin Exp Metastasis 2014;31:977-89.
23. Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology 2013;145:1064-75.
24. Inamoto S, Itatani Y, Yamamoto T, Minamiguchi S, Hirai H, Iwamoto M, et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of myeloid-derived suppressor cells through the CCL15-CCR1 chemokine axis. Clin Cancer Res 2016;22:492-501.
25. Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, et al. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol 2006;149:666-75.
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
27. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-94.
28. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011;11:519-31.
29. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-92.
30. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-30.
31. Pardigol A, Forssmann U, Zucht HD, Loetscher P, Schulz-Knappe P, Baggiolini M, et al. HCC-2, a human chemokine: Gene structure, expression pattern, and biological activity. Proc Natl Acad Sci U S A 1998;95:6308-13.
32. Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 2005;174:7341-51.
33. Joubert P, Lajoie-Kadoch S, Wellemans V, Létuvé S, Tulic MK, Halayko AJ, et al. Expression and regulation of CCL15 by human airway smooth muscle cells. Clin Exp Allergy 2012;42:85-94.
34. Park KH, Lee TH, Kim CW, Kim J. Enhancement of CCL15 expression and monocyte adhesion to endothelial cells (ECs) after hypoxia/reoxygenation and induction of ICAM-1 expression by CCL15 via the JAK2/STAT3 pathway in ECs. J Immunol 2013;190:6550-8.
35. Forssmann U, Magert HJ, Adermann K, Escher SE, Forssmann WG. Hemofiltrate CC chemokines with unique biochemical proterties: HCC-1/CCL14a and HCC2/CCL15. J Leukoc Biol 2001;70;357-66.
36. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 2008;3:117-24.
37. Li Y, Wu J, Zhang W, Zhang N, Guo H. Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer 2013;108:99-106.
38. Bodelon C, Polley MY, Kemp TJ, Pesatori AC, McShane LM, Caporaso NE, et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol 2013;24:2073-9.
39. Li Y, Yu HP, Zhang P. CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma. Hepatol Int 2016;10:488-92.
40. Rodero MP, Auvynet C, Poupel L, Combadiere B, Combadière C. Control of both myeloid cell infiltration and angiogenesis by CCR1 promotes liver cancer metastasis development in mice. Neoplasia 2013;15:641-8.
41. Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med 2015;212:1043-59.
42. Gladue RP, Brown MF, Zwillich SH. CCR1 antagonists: What have we learned from clinical trials. Curr Top Med Chem 2010;10:1268-77.
43. Szekanecz Z, Koch AE. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat Rev Rheumatol 2016;12:5-13.